Since TGF-β is a transcriptional regulator, we analyzed the transcriptional signature of rounded and highly contractile A375M2 melanoma cells compared to A375M2 cells treated with contractility inhibitors (ROCK inhibitors H1152, Y27632, and blebbistatin, an inhibitor of Myosin II ATPase) or less contractile A375P cells [26]. This evidence concerns the gene TGFB1 and melanoma.